Greater Manchester Medicines Management Group

Greater Manchester Clinical Standards Board



<< Back

News Summary

From this page you will be able to access a summary of additions or changes to the GMMMG website during June 2019

June 2019


Pathways and Guidelines Development Subgroup (PaGDSG)


On behalf of the GMMMG Pathways and Guidelines Development Subgroup, an updated Greater Manchester-wide Shared Care Protocol for Paliperidone Long Acting Injection in Adults is in development. We now seek comments on this draft.  This consultation period is open until 5pm on the 24th July

Formulary and Managed Entry Subgroup (FMESG)


The following actions were proposed at the April 2019  FMESG meeting and will be sent to CSB for support.

  • Stiripentol for Dravet syndrome and SCN1A variant epilepsy – RED and GREY.
  • Triamcinolone (Kenalog) injection for allergic rhinitis to be GREY and GREEN (specialist advice)
  • Prucalopride  - restriction to use in women only to be removed, in line with the product licence.
  • Levonorgestrel intrauterine devices – first choice on formulary to be Kyleena, with Levosert as an alternative for patients with heavy menstrual bleeding. Mirena to be assigned a status of GREEN and GREY, for use only in women who require endometrial protection during oestrogen HRT
  • Hydrocortisone oral granules (Alkindi) to be added to the paediatric RAG list as GREEN (specialist initiation) for doses <5 mg only.
  • Dexamfetamine for narcolepsy to be AMBER, with an interim status of RED pending shared care protocol production.
  • Glycopyrronium oral solution to be GREEN (specialist initiation) for severe sialorrhoea
  • All relevant NICE guidelines and MHRA advice to be added to formulary, as appropriate.

We now seek comments on these proposals.  This consultation is open until 5pm on Thursday 18th July 2019.

<< Back



RSS Feed